Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps

Lubna Danish¹, Dirke Imig², Frank Allgöwer², Peter Scheurich¹, Nadine Pollak¹,²*

¹ Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany, ² Institute of Systems Theory and Automatic Control, University of Stuttgart, Stuttgart, Germany

* Nadine.pollak@izi.uni-stuttgart.de

Abstract

Dysregulation of the mitochondrial signaling pathway of apoptosis induction represents a major hurdle in tumor therapy. The objective of the presented work was to investigate the role of the intrinsic (mitochondrial) apoptotic pathway in the non-small lung cancer cell line NCI-H460 upon induction of apoptosis using the highly bioactive TRAIL derivative Db-scTRAIL. NCI-H460 cells were TRAIL sensitive but an only about 3 fold overexpression of Bcl-2 was sufficient to induce a highly TRAIL resistant phenotype, confirming that the mitochondrial pathway is crucial for TRAIL-induced apoptosis induction. TRAIL resistance was paralleled by a strong inhibition of caspase-8, -9 and -3 activities and blocked their full processing. Notably, especially the final cleavage steps of the initiator caspase-8 and the executioner caspase-3 were effectively blocked by Bcl-2 overexpression. Caspase-9 knock-down failed to protect NCI-H460 cells from TRAIL-induced cell death, suggesting a minor role of this initiator caspase in this apoptotic pathway. Rather, knockdown of the XIAP antagonist Smac resulted in enhanced caspase-3 degradation after stimulation of cells with TRAIL. Of note, downregulation of XIAP had only limited effects on TRAIL sensitivity of wild-type NCI-H460 cells, but resensitized Bcl-2 overexpressing cells for TRAIL-induced apoptosis. In particular, XIAP knockdown in combination with TRAIL allowed the final cleavage step of caspase-3 to generate the catalytically active p17 fragment, whose production was otherwise blocked in Bcl-2 overexpressing cells. Together, our data strongly suggest that XIAP-mediated inhibition of final caspase-3 processing is the last and major hurdle in TRAIL-induced apoptosis in NCI-H460 cells, which can be overcome by Smac in a Bcl-2 level dependent manner. Quantitative investigation of the XIAP/Smac interplay using a mathematical model approach corroborates our experimental data strengthening the suggested roles of XIAP and Smac as critical determinants for TRAIL sensitivity.
Introduction

Worldwide, lung cancer is the most common cause of cancer-related death in men and the third highest in women, being responsible for more than 1.5 million deaths in 2012 (World Cancer Report 2014, World Health Organization). Development of new treatment regimens for lung cancer like targeted therapy approaches is mandatory, because the success of conventional therapy is often limited due to acquired resistance [1]. Apoptosis is a tightly regulated form of controlled cellular self-destruction representing a major form of programmed cell death [2]. At the center of the cellular apoptotic program is a cascade of proteases, the caspases, the activation of which finally results in apoptosis. Caspases can be subdivided into a group of initiator caspases including caspase-2, -8, -9 and -10, and a group of executioner (effector) caspases including caspase-3, -6 and -7 [3]. Two main signaling pathways have been delineated to initiate the apoptotic program, called the extrinsic and the intrinsic pathway [4]. The extrinsic pathway is induced by activation of transmembrane receptors of the so called “death receptor” subgroup within the TNF receptor family which initiate apoptotic signals after binding their specific ligands. Activated death receptors recruit intracellular adapter molecules and form the death-inducing signaling complex (DISC) comprising procaspase-8/-10. These initiator caspases become subsequently cleaved and activated within the DISC. Once activated, they in turn cleave and activate downstream caspases, i.e. they initiate the caspase cascade.

The intrinsic apoptotic pathway is activated in response to signals resulting from severe cellular stress. Key event in this pathway is the permeabilization of the mitochondrial outer membrane (MOMP), whose integrity is mainly controlled by members of the Bcl-2 family. This large protein family consists of both pro- and antiapoptotic members which either induce or inhibit MOMP [5]. MOMP results in the release of soluble proapoptotic proteins into the cytosol, such as cytochrome c and second mitochondrial-derived activator of caspase (Smac/DIABLO). Cytochrome c initiates formation of the so-called apoptosome by promoting Apaf-1 oligomerization and triggering the activation of the initiator caspase-9, whereas Smac serves as a proapoptotic protein mainly by antagonizing the inhibitor of apoptosis (IAP) protein family member X-linked IAP (XIAP) [6].

In death receptor-mediated apoptosis two distinct cell types have been described, called type I and type II cells. In type I cells, caspase-8/-10 are directly and strongly activated within the DISC, allowing them to directly trigger a strong activation of the effector caspases caspase-3/-7 without a need for the involvement of the intrinsic pathway. On the other hand, in so-called type II cells, the mitochondrial pathway of apoptosis is required for amplification of the apoptotic signal [7]. In the center of this crosstalk of the two signaling pathways is the BH3-only protein Bid, becoming cleaved by activated caspase-8/-10 to truncated Bid (t-Bid). The latter then leads to activation of the proapoptotic Bcl-2 family members Bak and Bax within the outer mitochondrial membrane, resulting in MOMP allowing strong effector caspase activation and cell death [5].

The molecule TNF-related apoptosis-inducing ligand (TRAIL) is a member of the TNF ligand family and serves as a ligand for four cellular membrane receptors in the human system. Two of them, TRAILR1 and TRAILR2, are death receptors capable to activate the apoptotic program. The two other receptors, TRAILR3 and TRAILR4, are believed to mainly interfere with the proapoptotic effects of TRAIL by various mechanisms [8,9]. TRAIL is expressed on the cell surface as a type 2 transmembrane protein which can be released by proteolysis forming soluble TRAIL homotrimers. Interestingly, soluble TRAIL predominantly induces apoptosis in tumor cells, but not in normal tissues, and is well tolerated when given systemically [10]. However, clinical studies with soluble TRAIL so far showed only limited antitumoral effects [11]. Various attempts have been described to construct TRAIL-derived molecules possessing
stronger antitumoral bioactivity. These include TRAIL molecules of higher valency, or fusion proteins with antibody derivatives for tumor targeting [11,12].

The human non-small cell lung carcinoma (NSCLC) line NCI-H460 has been characterized intensively in literature as a chemoresistant cell line [13,14]. In the present work we aimed at investigation of the underlying molecular mechanisms regulating the intrinsic apoptotic pathway of NCI-H460 in response to a highly potent TRAIL derivative, Db-scTRAIL [12]. This molecule possesses a higher valency (six versus three TRAIL monomers in a single molecule) and binds in addition with higher avidity due to targeting of epidermal growth factor (EGF) receptors with its antibody part. Db-scTRAIL is capable to also modify EGF signaling in EGF receptor (EGFR) positive and responsive cells, but the latter can be excluded in NCI-H460 cells, because these carry a KRAS mutation and have been shown to be unresponsive to EGF (M. Olayioye, unpublished data). Accordingly, in NCI-H460 cells Db-scTRAIL simply acts as a TRAIL derivative with enhanced affinity and receptor crosslinking activity, but without affecting EGFR signaling.

Here we show that Db-scTRAIL efficiently induces apoptosis in these cells in a mitochondria-dependent manner. Interestingly, apoptosis induction of these type II cells is strongly dependent on the mitochondrial release of Smac, rather than cytochrome c-mediated activation of caspase-9. TRAIL sensitivity/resistance in dependence of the expression level of Bcl-2 is crucially controlled by XIAP, the major antagonist of effector caspase-3. In line with these results, inhibition of apoptosis by Bcl-2 occurs at late steps of the proteolytic activation cascade of caspases. Applying mathematical models to analyze and predict responsiveness of cancer cells has emerged as a powerful tool [15,16]. We here adopt a mathematical description of the XIAP/Smac binding reaction to scrutinize our experimental results. In accordance with our data the model describes regions of TRAIL sensitivity and resistance, respectively, in NCI-H460, supporting the crucial role of the intrinsic pathway in apoptotic execution triggered by death receptor activation.

Results

Moderate Bcl-2 overexpression effectively protects NCI-H460 cells from TRAIL-induced apoptosis

NCI-H460 cells have been described as type II cells in literature, representing cells where death receptor-induced apoptosis is dependent on the mitochondrial apoptotic pathway to amplify effector caspase activation [17]. The reason for this dependency is believed to be caused by a comparably weak activation of the initiator caspases-8/-10 within the DISC [7]. To analyze the relevance of the mitochondrial pathway for efficient apoptotic signaling in response to the dimerized targeted Db-scTRAIL, a subline of NCI-H460 stably overexpressing a FLAG-tagged Bcl-2 molecule (NCI-H460/Bcl-2) was established (Fig 1A). Note that the tagged Bcl-2 protein appears at a somewhat lower molecular weight range as compared to endogenous Bcl-2 suggesting that we overexpressed the smaller alternative spliced isoform β [18]. Overexpression of Bcl-2 was comparably low, we estimated from intracellular cytofluorometric analyses (Fig 1B) a factor in the range of about 3. Nevertheless this subline showed strong TRAIL resistance in comparison to wildtype cells (Fig 1C and 1D), confirming a cell type II for NCI-H460. This data already indicated that TRAIL receptor-mediated induction of apoptosis in NCI-H460 cells is a process quite sensitively regulated.

Control experiments confirmed that TRAIL-induced cell death is in fact apoptosis, because the broad range caspase inhibitor zVAD-fmk efficiently protected NCI-H460 cells (Fig 1D). Further, a strong release of the mitochondrially located molecules cytochrome c and Smac/DIABLO into the cytosol could be observed, beginning after about 2 h of TRAIL stimulation.
in wildtype NCI-H460 cells, but not in Bcl-2 overexpressing cells (Fig 1E). As expected, the latter cells, being highly unresponsive to TRAIL treatment per se, were effectively resensitized to a TRAIL stimulus in the presence of the cell permeable Bcl-2 inhibitor ABT-737 (Fig 1F). Again, cell death could be efficiently inhibited by the pan caspase inhibitor zVAD-fmk.

Overexpression of Bcl-2 showed no effects on the surface expression of TRAIL receptors, EGFR or on the expression levels of caspase-8, caspase-3 and XIAP (S1 Fig). Interestingly, when we analyzed the mitochondrial membrane potential (MMP) using TMRM as fluorescent probe, we observed a fraction of approximately 30% of all cells within the population showing reduced MMP (S1 Fig). Notably, Bcl-2 overexpression rescued this heterogeneity within the cell population. As differences in the MMP have been linked to apoptosis resistance [19,20], we monitored TMRM-stained cells by live-cell imaging and quantified the time from TRAIL treatment to death as a function of the cellular TMRM intensity for individual cells. However, we observed no correlation of the time to death values with the MMP (S1 Fig).
**Bcl-2 overexpression strongly inhibits caspase activity but affects caspase cleavage preferentially at late activation steps**

Investigating the enzymatic activities of the caspases -8, -9 and -3 we found increasing values in response to TRAIL stimulation peaking after about 6 to 8 h of stimulation (Fig 2A). As expected, the enzymatic activities of all three caspases were strongly reduced in the cells overexpressing Bcl-2, which were effectively protected from TRAIL-mediated apoptosis (Fig 2A). Caspases become activated by sequential enzymatic cleavage steps, Western blotting experiments revealed distinct cleavage pattern as shown in Fig 2B. For caspase-8 the initial cleavage step to the p41/p43 products became visible after about two hours of TRAIL stimulation and their amounts increased up to about six hours of stimulation. Interestingly, this initial cleavage step, believed to occur within the death receptor signaling complex DISC [21], was comparable for NCI-H460 wildtype cells and the Bcl-2 overexpressing cells, strongly suggesting that p41/p43 production was not dependent on the mitochondrial signaling pathway, e.g. in terms of a caspase-9/caspase-3-mediated positive feedback on caspase-8 cleavage [22]. Clearly, however, the final caspase-8 cleavage, resulting in formation of the cytosolically located p18 product [23], could be detected in wildtype cells only, but not in NCI-H460/Bcl-2 cells (Fig 2B). In a similar way, the cleavage kinetics and pattern of caspase-3 to the p19 product was comparable for both cell lines, but the subsequent step leading to the enzymatically highly active p17 product was blocked in the Bcl-2 overexpressing cells (Fig 2B). Caspase-9 cleavage was detected after

---

**Fig 2. Bcl-2 overexpression strongly inhibits caspase activity but affects caspase cleavage preferentially at late activation steps.** (A) Cells were stimulated with Db-scTRAIL (1 nM) for the indicated time periods. Whole protein lysates were incubated with fluorogenic caspase substrates Ac-IEPD-AMC (caspase-8), Ac-DMQD-AMC (caspase-3) and Ac-LEHD-AMC (caspase-9), respectively. Increasing fluorescence values were measured every 2 min for 2 h at λ = 460 nm. Data points shown, representing slopes, are mean values ± SD calculated from 3 independent experiments, normalized to the highest value of each experiment. (B) Cells were stimulated with Db-scTRAIL (1 nM) up to 8 h, one group was left untreated as a control. Equal amounts of whole cell lysates were subjected to immunoblot analysis using antibodies specific for cleaved caspase-8, cleaved caspase-3 and caspase-9 followed by HRP-conjugated secondary antibody.

https://doi.org/10.1371/journal.pone.0198203.g002
2–3 h of TRAIL treatment paralleling cytochrome c and Smac release in response to MOMP (Fig 1E) and this processing was significantly blocked after Bcl-2 overexpression. Notably, the onset of caspase-9 cleavage after Db-scTRAIL apparently precedes measurable bioactivity. We propose that caspase-9 cleavage occurs irrespective from its bioactivity that requires apoptosome formation [24,25].

**Caspase-9 plays a minor role only in TRAIL-induced apoptosis in NCI-H460 cells**

In type II cells caspase-9 is believed to play an important role amplifying the caspase cascade in a mitochondria-dependent manner [26,27], although some publications have challenged this as a general rule [23,28–30]. Clearly, caspase-9 activity (Fig 2A) and cleavage (Fig 2B) were inhibited in the Bcl-2 overexpressing cells, where the mitochondrial pathway appears to be effectively inhibited as no cytochrome c release can be observed (Fig 1E). However, whether strong activation of caspase-9 observed in wildtype cells is causal for effective apoptosis or rather represents a bystander effect, was unclear. We therefore used the caspase-9-specific inhibitor z-LEHD-fmk and in addition downregulated caspase-9 using a siRNA approach. As presented in Fig 3A, z-LEHD-fmk conferred no significant protection of NCI-H460 cells over a broad concentration range of TRAIL. Similarly, although an effective downregulation of procaspase-9 could be achieved as demonstrated by Western blotting (Fig 3B), no significant effects on TRAIL sensitivity of these cells was noted (Fig 3C). In fact, comparable pattern of caspase-3 cleavage were observed in control siRNA-treated cells and cells with downregulated caspase-9 (Fig 3D). Although the caspase-9 cleavage pattern were hard to compare in the two cell lines due to

![Fig 3](https://doi.org/10.1371/journal.pone.0198203.g003)

**Fig 3. Caspase-9 plays only a minor role in TRAIL-induced apoptosis in NCI-H460 cells.** (A) Cells were preincubated with caspase-9 inhibitor (z-LEHD-fmk, 50 μM) for 1 h, followed by stimulation with serial dilutions of Db-scTRAIL for 24 h. Viable cells were stained with crystal violet and absorbance was measured at 550 nm. (B) Western blot showing efficient downregulation of procaspase-9 by siRNA treatment. NCI-H460 cells were transfected with siRNAs (siControl and siCaspase-9) and harvested after 48 h. (C) NCI-H460 cells with downregulated caspase-9 do not show increased TRAIL resistance. Cells transfected with either non-targeting (siControl) or caspase-9 (siCaspase-9) siRNAs were stimulated 48 h post transfection with serial dilutions of Db-scTRAIL for further 24 h. (D) Cells pretreated as in (B) were treated for 2 and 4 h with Db-scTRAIL (1 nM), control cells were left untreated. Whole cell lysates were subjected to western blot analysis using antibodies specific for caspase-9 and caspase-3, α-tubulin was used to confirm equal loading.
the differential expression levels of the proenzyme, these data also suggest no major differences (Fig 3D). Together, these results strongly suggest that either very low amounts of caspase-9 are sufficient to effectively enhance apoptosis after mitochondrial depolarization or that caspase-9 plays no major role in this regard in NCI-H460 cells.

Smac is an effective regulator of TRAIL-induced apoptosis in NCI-H460 cells

A well characterized regulator of apoptosis released into the cytosol upon mitochondrial depolarization is the molecule Smac/DIABLO, representing an efficient antagonist for XIAP, but also inhibiting cIAP1 and cIAP2, thereby repressing their antiapoptotic activities [31]. Small molecule-based Smac mimetics have been designed based on the structure of the N-terminal tetrapeptide of native Smac, which are capable to bind a surface groove on the baculovirus repeat 3 (BIR3) domain of XIAP (reviewed in [32]). We used the Smac mimic SM83, but TRAIL sensitivity of NCI-H460 cells was hardly affected by this molecule (Fig 4A). However, Bcl-2 overexpressing cells, showing strong protection against TRAIL-induced apoptosis, were efficiently resensitized to TRAIL by treatment with SM83 (Fig 4B). These data underscore the importance of mitochondrial depolarization in TRAIL-mediated cell death in NCI-H460 cells, pointing to the interplay between XIAP and Smac as a central regulatory circuit controlling final activation of caspase-3. We therefore downregulated Smac using a siRNA approach and

![Fig 4. Smac is a potent regulator of TRAIL-induced apoptosis in NCI-H460 cells.](https://doi.org/10.1371/journal.pone.0198203.g004)
investigated the level of caspase-3 activation. Not quite unexpected, an efficient downregulation of the Smac protein (Fig 4C) resulted in strongly reduced caspase-3 p19 and p17 levels in comparison to the control (Fig 4D). Cleavage products of caspase-3 are known substrates for XIAP ubiquitin ligase activity [33], consequently, we observed enhanced caspase-3 processing when we added the proteasome inhibitors Bortezomib or MG 132 (Fig 4D) while Bortezomib alone was insufficient for caspase-3-mediated cell death (Fig 4E and 4F).

**Overexpression of XIAP or of XIAP subdomains hardly affects TRAIL sensitivity**

Since the data obtained with the Smac mimetic SM83 and with downregulation of endogenous Smac protein pointed to a central role of the apoptosis inhibitor XIAP, we next overexpressed this molecule as well as the BIR2 and BIR3 subdomains thereof. Transfection efficiencies were somewhat variable, as controlled optically by immunoblotting, demonstrating the proper molecular weights of the respective GFP fusion proteins (Fig 5A and 5B). Compared to the relevant transfection control, no significant changes in TRAIL sensitivity could be observed, neither at lower, nor at high ligand concentrations used (Fig 5C). These results suggest that neither enhancement of the XIAP protein level nor expression of its subdomains BIR2 or BIR3 causes additional protection against TRAIL-mediated apoptosis. Alternatively, but according to our suggestions more unlikely, the transfection efficiencies were too low for significant effects visible in the whole cell population.

**XIAP downregulation restores TRAIL sensitivity in Bcl-2 overexpressing cells**

As enhancement of the protein level of XIAP was not found to exert any significant effects on TRAIL sensitivity, we downregulated its endogenous level using a siRNA approach.

![Image](https://doi.org/10.1371/journal.pone.0198203.g005)
Downregulation was efficient as shown in Fig 6A, whereas the protein levels of the two IAP family members cIAP-1 and survivin were unaffected. Downregulation of XIAP in fact resulted in some limited enhancement in TRAIL sensitivity in control NCI-H460 cells, visible in particular at higher ligand concentrations (Fig 6B). Notably, in the Bcl-2 overexpressing cells a very strong sensitization could be observed for these otherwise resistant cells (Fig 6C). The type of cell death was apoptosis, as the broad caspase inhibitor zVAD-fmk fully blocked TRAIL-induced apoptosis in NCI-H460/Bcl-2 cells with downregulated XIAP (Fig 6C). As expected, reduced XIAP levels were associated with enhancement of caspase processing (Fig 6D). For caspase-3, we observed the formation of fully processed p17 fragment from intermediate product p19 while this conversion was completely blocked in control-transfected cells. This indicated that cells expressing low XIAP levels may switch to a mitochondria-independent, i.e. type I cell response. Active caspase-3 p17 the in turn feeds back on caspase-8, resulting in formation of its fully processed p18 form and also on caspase-9 cleavage (Fig 6D).

Mathematical modeling of the XIAP/Smac interplay in NCI-H460 cells

The interaction of XIAP and Smac is believed to be pivotal for regulation of sensitivity to Db-scTRAIL. To analyze the consequences of variations in the amounts of these two proteins for the apoptotic response, we analyzed the XIAP/Smac complex formation mathematically, i.e. neutralization of XIAP and caspase-3 p19 processing. To this we determined the initial molecule numbers of XIAP and Smac in unstimulated NCI-H460 cells (Fig 7A) and analyzed the complex formation mathematically, based on reaction rates from literature [16]. As model output we chose the amount of Smac-free XIAP in steady state (XIAP°). Dependent on the respective amounts of XIAP and Smac, three different regions of the cellular status were defined:
wild type (i.e. living cells which are TRAIL sensitive, colorless), ongoing cell death development (red) and TRAIL resistant property (green) (Fig 7B). Experimental conditions were allocated into this classification scheme. We assumed that cells become resistant to Db-scTRAIL treatment when XIAP concentration exceeds that of wild type by a factor of 2.5. As a result, reducing Smac protein level by 50% would result in only a moderate resistance to TRAIL (scenario I, Fig 7B and 7C). This is in line with data from Smac siRNA experiment (Fig 4A) and Bcl-2 overexpression (Fig 4B) which acts mainly through a reduction of cytoplasmic Smac. On the other hand, Db-scTRAIL sensitivity is assumed to increase when XIAP falls below 25%. Accordingly, a reduction of XIAP to about 50% would lead only to slightly enhanced apoptosis (scenario II, Fig 7B), a prediction matching nicely our experimental data (Fig 6B). The combination of both reduced XIAP and Smac (scenario III) results in a wild type behavior which is in accordance with the experimental results shown in Fig 6C. The approach explains that moderate enhancement of either XIAP or Smac is not to affect the cellular phenotype (scenario IV and V), whereas very high amounts of Smac should lead to a sensitization. Taken together, our experimental data can be reconciled with the calculated XIAP states.

Discussion

The molecule TRAIL is capable to induce apoptosis in the human system by binding to two membrane receptors, TRAILR1 and TRAILR2. In NCI-H460 cells these two molecules are both expressed at the cell surface at near to equal levels, whereas the two antagonistic receptors TRAILR3 and TRAILR4 can be hardly detected. Effective interference of the antagonistic receptors with the respective agonists is therefore highly unlikely in these cells. Many tumor cells are sensitive to TRAIL treatment whereas normal cells typically display TRAIL resistance [10,34]. However, these differential cellular response patterns are by no means absolute, as e.g. artificially crosslinked TRAIL is strongly toxic for normal hepatocytes [35], and many tumor...
cells show strong TRAIL resistance [10]. In the present publication we used a targeted and multimeric form of TRAIL, engineered to possess high bioactivity, but still well tolerated in vivo [12]. A detailed analysis of the Db-scTRAIL-induced apoptotic signaling pathway in the NSCLC line NCI-H460 revealed the following four major findings.

First, Bcl-2 is capable to effectively protect NCI-H460 cells from TRAIL-induced apoptosis after only a moderate upregulation. This points to an important role of Bcl-2 in our model cell line and in fact abnormal expression of Bcl-2 has been reported in lung cancer than in adjacent non-cancerous tissues and Bcl-2 is discussed as a prognostic factor [36–39]. Further, Bcl-2 overexpression has been described to induce chemo- and radiotherapy resistance in NCI-H460 cells [40]. The Bcl-2 inhibitor Venetoclax (ABT-199) was recently approved for the treatment of chronic lymphocytic leukemia and is currently tested in several ongoing clinical trials to treat multiple hematological malignancies [41]. Bcl-2 represents a promising target also in lung carcinoma [42,43]. The combination of Venetoclax with inhibition of XIAP activity by Smac mimetics offers an attractive way to enhance death receptor-mediated apoptosis [44,45].

When we investigated the mitochondrial status in NCI-H460 cells we found a significant heterogeneity of the mitochondrial potential within the cellular population which could not be observed in six control cell lines derived from different tumors. Differences in mitochondrial activity have been linked to drug resistance [19,20]. However, we detected no direct effect of low or high mitochondrial potential on TRAIL sensitivity. Notably, Bcl-2 overexpressing NCI-H460 cells also showed a homogeneous and high mitochondrial membrane potential.

Second, Smac appears to be a central regulatory molecule in the mitochondrial amplification of caspase activation, rather than caspase-9. In accordance with these data apoptosis induced by chemotherapeutics in NCI-H460 cells was found to be mediated by caspase-8 and effector caspases and was dependent on activation of the mitochondrial pathway, but not on caspase-9 activation [13]. In fact, at least for some cell lines caspase-9 activation appears not to be required for death receptor-mediated apoptosis in a type II cell, although activation of the mitochondrial pathway was mandatory [28,29,46]. In general, however, caspase-9 is considered to be essential for apoptotic signaling through the mitochondrial pathway [47]. However, the exact role of caspase-9 cleavage and activity during apoptosis remains questionable [24,48]. Clearly, Smac is a multifunctional molecule capable to interact with the BIR3 of XIAP for direct inhibition, but also favoring proteasomal degradation. Accordingly, Smac has been suggested to efficiently promote apoptosome-mediated activation of effector caspases [49]. On the other side Smac-deficient mice appear healthy and cell lines derived thereof showed normal apoptotic responses to some stimuli although caspase-3 activation induced by cytochrome c was clearly inhibited [50].

Third, the molecule XIAP obviously plays a pivotal role controlling the apoptotic machinery far at the end of the caspase cascade. This has been already suggested from the described importance of Smac, representing a direct antagonist of this molecule. It therefore appears likely that control of effector caspases by the two opposing molecules Smac and XIAP represents the final hurdle before the cell becomes dismantled by a strong activation of effector caspases. These results are in accordance with those from Jost and colleagues, who found XIAP to be a central regulator in CD95/Fas-induced apoptosis, controlling whether a cell responds as a type I or a type II cell [32]. Similarly, cooperativity between XIAP inhibitors and TRAIL resulted in a strong apoptotic response in pancreatic carcinoma or leukemia cells, capable to even overcome a Bcl-2-mediated resistance [51,52].

Focusing on the complex formation of XIAP and Smac, a mathematical description of the reversible binding reaction reproduces our experimental findings. As the molecule number of Smac is in excess compared to XIAP, moderate downregulation of Smac is predicted to hardly
affect TRAIL sensitivity. In addition, the effect of downregulated Smac can be overcome by XIAP downregulation. Definition of regions of sensitivity and resistance in dependence of the initial amount of XIAP and Smac may help to classify and design further experimental setups. Fourth, interesting pattern in the sequential activation of caspase-3 were detected, all indicating that control of the caspase cascade by Bcl-2 is located late in this processes of sequential caspase cleavage. In particular initiator caspase-mediated initial cleavage of caspase-3 between the large and small subunits to generate the p19 fragment occurred with similar kinetics in TRAIL sensitive wildtype NCI-H460 cells and the Bcl-2 overexpressing resistant variant (Fig 2B). In contrast, the final autocleavage step to generate the fully active p17 fragment of caspase-3 was blocked in Bcl-2 overexpressing cells (Fig 2B). A likely explanation for this result argues that XIAP is capable to effectively inhibit caspase-3 maturation in NCI-H460/Bcl-2 cells, whereas the initial caspase-3 cleavage step can occur unhampered in the DISC. The fact that caspase-8 cleavage occurs significantly stronger in wild-type than in Bcl-2 overexpressing cells (Fig 2B) is therefore likely the consequence of a positive feedback loop leading from active effector caspases to caspase-8, thereby further enhancing activation of the caspase cascade [23]. The initial cleavage step of caspase-8 leading to formation of the p41/p43 product appears to occur at comparable levels in wild-type and Bcl-2 overexpressing cells (Fig 2B), which can be easily explained by its location in the DISC, unaffected by the consequences of Bcl-2 overexpression. Strong caspase-9 activation and cleavage can be observed in cells where the mitochondrial pathway becomes activated (Fig 3F), although our results question the importance of this activation step for the apoptotic event (see above).

Together, our results strongly suggest an interesting aspect of the mitochondrial apoptotic pathway. In type II cells its activation is mandatory for execution of the final apoptotic program. In cells, where caspase-9 activity is indispensable for execution of the apoptotic program, surviving cells might stay in a status with only weakly activated caspase cascade. In NCI-H460 cells in contrast, where Smac but not caspase-9 activity appears to be mandatory for induction of cell death, surviving cells are likely to have a strongly activated caspase cascade, controlled at the last step of caspase-3 activation. These results are of particular interest with a view to recent data showing that sublethal caspase activity allows cells to escape from apoptosis, but surviving cells accumulate DNA damage and rather promote tumor development [53,54].

Materials and methods

Maintenance of cell lines and cytotoxicity assay

The cell lines NCI-H460, HeLa and HCT-116 were obtained from ATCC (Manassas, USA). Cells were cultured in RPMI-1640 medium supplemented with L-glutamine and 5% fetal calf serum (FCS) and kept at 37°C with 5% CO₂ and 96% relative humidity. Transfectants of NCI-H460 cells stably overexpressing Bcl-2 (NCI-H460/Bcl-2) were supplemented with culture medium containing 3 μg/ml puromycin. For cytotoxicity assays 15000 cells per well were plated in 96-well flat bottom plate. Next day cells were treated with serial dilutions of Db-scTRAIL starting with 1 nM. Cell viability was determined by crystal violet staining after 24 h and absorbance was measured in a microplate reader at λ = 550 nm (Infinite M200, Tecan). All values were normalized to those from unstimulated wells. Alternatively, cells were harvested, stained with Annexin V-FITC and propidium iodide (PI) and cell viability was determined by flow cytometry (MACSQuant®, MiltenyiBiotec, Germany).

Antibodies and reagents

Following antibodies were used: Rabbit polyclonal anti-Bcl-2, rabbit monoclonal anti-caspase-3 (8G10), mouse monoclonal anti-caspase-8 (1C12), anti-Smac/DIABLO, rabbit polyclonal
anti-caspase-9, rabbit monoclonal anti-c-IAP1 (D5G9) and rabbit monoclonal anti-Survivin (71G4B7) antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). Mouse monoclonal anti-XIAP and mouse monoclonal anti-cytochrome c were from BD Pharmingen (Heidelberg Germany). Goat polyclonal anti-β-actin was from Santa Cruz Biotechnology (California, USA), anti-α-tubulin was purchased from Sigma-Aldrich (Taufkirchen, Germany). Mouse monoclonal anti-GFP was from Roche Diagnostics (Mannheim, Germany). Mouse monoclonal antibodies anti-TRAIL receptors 1–4 were from R&D Systems (Minneapolis, Minnesota, USA), mouse anti-human EGFR from BioLegend (San Diego, USA). Corresponding mouse IgG1 and IgG2b isotype control antibodies were obtained from BioLegend and phycoerythrin-conjugated goat anti-mouse IgG+IgM was from Dianova (Hamburg, Germany). Caspase substrates, Ac-DMQD-AMC (caspase-3), Ac-IEPD-AMC (caspase-8) and Ac-LEHD-AMC (caspase-9) were from Enzo Life Sciences, Switzerland. Caspase-9 inhibitor z-LEHD-fmk was from R&D systems and Bcl-2 family inhibitor ABT-737 was from Santa Cruz Biotechnology (California, USA). TMRM was from Thermo Fisher Scientific (USA) and Annexin V-FITC/PI was obtained from BD Pharmingen. Diabody-single chain TRAIL directed against EGFR (DbαEGFR-scTRAIL), shortly termed Db-scTRAIL [12], was kindly provided by Dr. Martin Siegemund, Institute of Cell Biology and Immunology, University of Stuttgart, Germany. Stock solutions of Db-scTRAIL were freshly diluted with culture medium to the indicated final concentration for each experiment. Smac mimetic SM83 was produced as described before [55].

**Caspase activity assay**

Briefly, cells from both cell lines (NCI-H460 and NCI-H460/Bcl-2) were stimulated with 1 nM Db-scTRAIL for the indicated times, washed with PBS, harvested and pelleted. Cells were then lysed using caspase lysis buffer with freshly added protease inhibitor cocktail (Roche Diagnostics, Germany) incubated on ice and centrifuged at 13000 × g at 4˚C for 10 min. Protein concentration was determined by Bradford assay. 4 μg of total protein was used to determine caspase-3 activity, while 32 μg were used for caspase-8 and 20 μg for caspase-9 activity determination. Cell lysates were transferred to the wells of a black 96-well plate and mixed with caspase activity buffer (10 mM HEPES pH 7.0, 220 mM mannitol, 68 mM sucrose, 2 mM NaCl, 2.5 mM KH₂PO₄, 0.5 mM EGTA, 2 mM MgCl₂, 5 mM pyruvate, 1mM DTT), containing the appropriate caspase substrate. The changes in fluorescence intensity were detected using a microplate reader each 2 min for 2 h at 37˚C. Enzymatic activities were calculated from the slopes of the resulting lines and normalized to the highest value.

**Cell lysis and subcellular fractionation**

Cells were stimulated, harvested and pelleted by centrifugation, washed with PBS and resuspended in lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM Na₂EDTA, 1 mM EGTA, 1% (v/v) Triton X-100) with freshly added protease inhibitor. After 15 min incubation on ice, samples were centrifuged at 13000 × g at 4˚C for 10 min. Protein concentration was determined by Bradford assay. For subcellular fractionation, cells stimulated for the indicated time points were collected, and lysed in a permeabilization buffer containing 200 μg/ml digitonin for 5 min. Plasma membrane permeabilization was checked by trypan blue staining and the lysate after centrifugation for 10 min at 2000 × g was used as mitochondrial fraction. The pellet was resuspended in lysis buffer containing 1% Triton-X100 and incubated on ice for 15 min, centrifuged at 13000 × g for 10 min and supernatants were transferred to new reaction tubes.
Western blotting

Cell samples were separated by SDS-PAGE and transferred onto nitrocellulose membrane. Membranes were probed with horseradish peroxidase-conjugated α-mouse IgG or α-rabbit IgG secondary antibodies (Dianova, Hamburg, Germany) and immunodetection was performed using the ECL system (Thermo Fisher Scientific, USA). Membranes were stripped with 0.2% NaOH before reprobing using different antibodies.

Flow cytometry

For intracellular staining of Bcl-2, cells were harvested, pelleted and fixed with 4% paraformaldehyde. After washing with PBA (PBS supplemented with 0.05% (w/v) BSA and 0.02% (w/v) NaN₃), cells were permeabilized with FACS™ permeabilization solution 2 (BD Pharmingen, Germany), and incubated with primary antibody diluted in PBA supplemented with 10% FCS for 60 min on ice followed by two washing steps. Cells were then incubated with PE-labeled secondary antibody diluted in PBA supplemented with 10% FCS and subsequently analyzed by flow cytometry (MACSQuant™, MiltenyiBiotec, Germany).

For staining of EGFR and TRAIL receptors, cells were resuspended in PBA containing primary antibody. After incubation for 45 min on ice, cells were washed in PBA and incubated with PE-conjugated secondary antibody in PBA. After 45 min of incubation cells were washed again and analyzed by flow cytometry. TMRM was used to analyze the mitochondrial membrane potential. Cells were loaded with 60 nM TMRM diluted in cell culture media for 30 min, harvested, washed with PBA and analyzed by flow cytometry.

Time-lapse microscopy

NCI-H460 cells were cultivated on 35 mm glass bottom dish. Next day, medium was replaced by phenol red-free medium containing 5% FCS and 60 nM TMRM and the dish was placed in the incubation chamber (37˚C, 5% CO₂) of the Zeiss Cell Observer microscope (Zeiss, Germany) equipped with a 20x objective and a CCD camera. Apoptosis was induced with 1 nM Db-scTRAIL and cells were then imaged in 15 min interval for 6 h. TMRM was excited using the 587 nm laser and fluorescence was detected at 610 nm. Image analysis was done with Zen Blue software (Zeiss). TMRM intensity, corresponding cell size and the time from Db-scTRAIL addition to apoptotic cell death were analyzed for 100 cells. Cells were classified as apoptotic at the time of first appearance of membrane blebbing and cell shrinkage, typical signs of apoptosis.

Cloning of BIR domains

The gene sequences encoding full length XIAP, the BIR2 (aa 126–229) or BIR3 (aa 244–352) domains were amplified using appropriate primers from plasmid pCDNA3.1-myc-XIAP (kindly provided by D. Kulms, Dresden, Germany) and cloned into pEGFP-C1 (Clontech) using EcoRI and XhoI sites. Resulting expression constructs were verified by DNA sequencing (GATC Biotech AG, Konstanz, Germany).

Transfections

For transient expression of full length XIAP and its BIR domains, cells were nucleofected using Amaxa Nucleofector™ Kit T (Lonza, Switzerland) according to the manufacturer’s instructions. Transfection efficiency was checked after 24 h by GFP positive cells under the microscope and afterwards cells were harvested and analyzed for the protein levels of XIAP and BIR domains by immunoblotting using anti-GFP antibody. Cells were transfected with...
either control or gene-specific siRNAs from Silencer Select (Fisher Scientific GmbH, Germany) at a final concentration of 8 nM using DharmaFECT (Dharmacon, GE healthcare, UK) according to manufacturer’s instructions. Protein expression levels were analyzed via western blotting 24 h post transfection.

Quantification of initial concentration of XIAP and Smac in NCI-H460

The cellular molecule number of XIAP was determined by quantitative western blotting. First, HeLa cells were transfected with plasmid GFP-XIAP using Lipofectamine LTX & Plus (Life technologies). Cells were lysed 48 h later and increasing amounts of total cell lysates were subjected to western blotting in parallel with increasing amounts of recombinant purified GFP and different amounts of cell lysates of NCI-H460 cells. Anti-GFP and anti-XIAP were used for detection of GFP, GFP-XIAP or XIAP, respectively. GFP-XIAP intensities were compared with purified GFP, and the XIAP amount in HeLa and NCI-H460 cells was calculated from GFP-XIAP intensities, respectively. We consider the unit molecule numbers/cell more illustrative than the unit molar and used an average cell volume of 3.1 pL [56]. Three experiments were evaluated. Smac molecule number was determined by comparative quantitative western blotting. HCT-116 cells were used as reference cell line [57]. Total cell extracts from NCI-H460 and HCT-116 cells were compared for their XIAP intensity by western blotting. Three experiments were analyzed.

Mathematical model and implementation

To validate the experimental results, a minimal mathematical model was analyzed. The model consists of three ordinary differential equations that describe the reversible binding of Smac and XIAP [16]. Therefore, we used the initial conditions of Smac and XIAP for NCI-H460. As model output, steady state values of Smac-free XIAP (XIAP\(^\text{a}\)) were calculated in dependence on different initial amounts of Smac and XIAP, representing experimental conditions. XIAP\(^\text{a}\) represents the relevant amount of XIAP blocking the processing of activated caspase-3 p19 form. All calculations were performed with MATLAB release 2017a (The MathWorks, Inc., Natick). First, the amount of XIAP\(^\text{a}\) was calculated for the wildtype scenario. This value serves as reference value and was set to 100%. XIAP\(^\text{a}\) values derived from scenario I and II were used for determining threshold values of XIAP\(^\text{a}\). Exceeding or deceeding the specific threshold implies increased resistance or sensitivity, respectively. The remaining scenarios were classified by their XIAP\(^\text{a}\) levels and compared to experimental data.

Supporting information

S1 Fig. Expression of apoptosis-related proteins is not altered by Bcl-2 overexpression in NCI-H460 cells. (A) Flow cytometric analysis of TRAIL receptor cell surface expression in NCI-H460 or NCI-H460/Bcl-2 cells. TRAILR1-4 were immunostained with mouse anti-TRAILR1-4 antibodies (black histogram) or the respective isotype control antibodies (grey histogram) followed by incubation with anti-mouse IgG-PE conjugated secondary antibody. (B) Cell surface expression of EGFR (red histogram) in NCI-H460 or Bcl-2 overexpressing cells, isotype control is shown as black histogram. (C) Total cell extracts of NCI-H460 or NCI-H460/Bcl-2 were immunoblotted using antibodies directed against Bcl-2, caspase-8, caspase-3 or XIAP. Tubulin-α was used as loading control. Blots shown are representative of three independent experiments. (D) NCI-H460 or Bcl-2 overexpressing cells were stained with 60 nM TMRM and analyzed by flow cytometry. (E) NCI-H460 cells loaded with TMRM were treated with Db-scTRAIL (1 nM) and imaged by live-cell fluorescence microscopy. Apoptotic cell death time values and respective cellular TMRM intensities were analyzed for randomly
chosen cells (n = 100).

Acknowledgments
The authors acknowledge funding from the German research foundation in the grant SCHE 349/10-1 and the German Federal Research and Education Ministry (BMBF) in the project “PREDICT.” We further thank Beate Budai for expert technical assistance and Dr. Martin Siegemund for the Db-scTRAIL.

Author Contributions
Conceptualization: Peter Scheurich.
Funding acquisition: Peter Scheurich.
Investigation: Lubna Danish, Nadine Pollak.
Project administration: Nadine Pollak.
Supervision: Frank Allgöwer, Peter Scheurich, Nadine Pollak.
Validation: Lubna Danish, Nadine Pollak.
Visualization: Lubna Danish, Dirke Imig, Nadine Pollak.
Writing – original draft: Lubna Danish, Peter Scheurich, Nadine Pollak.
Writing – review & editing: Dirke Imig, Frank Allgöwer, Nadine Pollak.

References
1. Shitivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, et al. Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014; 5(6): 1392–1433. https://doi.org/10.18632/oncotarget.1891 PMID: 24722523
2. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007; 35(4): 495–516. https://doi.org/10.1080/01926230701320337 PMID: 17562483
3. Fuentes-Prior P, Salvesen GS. The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J. 2004; 384(Pt2): 201–232. https://doi.org/10.1042/BJ20041142 PMID: 15450003
4. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006; 25(34): 4798–4811. https://doi.org/10.1038/sj.onc.1209638 PMID: 16892092
5. Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010; 11(9):621–32. https://doi.org/10.1038/nrm2952 PMID: 20683470
6. Saelens X, Festjens N, Vande Walle L, Van Gurp M, van Loo G, Vandenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene. 2004; 23(16): 2861–74. https://doi.org/10.1038/sj.onc.1207523 PMID: 15077149
7. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998; 17(6): 1675–1687. https://doi.org/10.1093/emboj/17.6.1675 PMID: 9501089
8. Merino D, Laloue N, Morizot A, Schneider P, Solary, E, Micheau O. Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2. Mol Cell Biol. 2006; 26(19): 7046–7055. https://doi.org/10.1128/MCB.00520-06 PMID: 16980609
9. Neumann S, Hasenauer J, Pollak N, Scheurich P. Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes. J Biol Chem. 2014; 289(23): 16576–16587. https://doi.org/10.1074/jbc.M114.559468 PMID: 24764293
10. Walczak H, Miller RE, Arai K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999; 5(2):157–163. https://doi.org/10.1038/5517 PMID: 9930862
11. de Miguel D, Lemke J, Anel A, Walczak H, Martinez-Lostao L. Onto better TRAILs for cancer treatment. Cell Death Differ. 2016; 23(5):733–747. https://doi.org/10.1038/cdd.2015.174 PMID: 26943322
12. Siegmund M, Pollak N, Seifert O, Wahl K, Hanak K, Vogel A, et al. Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity. Cell Death Dis. 2012; 3:e295. https://doi.org/10.1038/cddis.2012.29 PMID: 22495350
13. Ferreira CG, Span SW, Peters GJ, Kruyt FA, Giaccone G. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small lung cancer cell line NCI-H460. Cancer Res. 2000; 60(24):7133–7141. PMID: 11156422
14. Yang L, Mashima T, Sato S, Mochizuki M, Sakamoto H, Yamori T, et al. Predominant suppression of apoptosis by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells. Cancer Res. 2003; 63(4):831–837. PMID: 12591734
15. Huber HJ, Rehm M, Pichut M, Düssmann H, Prehn JH. APOPTO-CELL—a simulation tool and interactive database for analyzing cellular susceptibility to apoptosis. Bioinformatics. 2007; 23(5):648–50. https://doi.org/10.1093/bioinformatics/btl684 PMID: 17237051
16. Aldridge BB, Gaudet S, Lauffenburger DA, Sorger PK. Lyapunov exponents and phase diagrams reveal multi-factorial control over TRAIL-induced apoptosis. Mol Syst Biol. 2011; 7:553. https://doi.org/10.1038/msb.2011.85 PMID: 22108795
17. Sun SY, Yue P, Zhou JY, Wang Y, Choi Kim HR, Lotan R, et al. Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem Biophys Res Commun. 2001; 280(3):788–797. https://doi.org/10.1006/bbrc.2000.4218 PMID: 11162590
18. Mazzocco K, Scaruffi P, Gambini C, Negri F, Tonini GP. Apoptosis and expression of bcl-2 α, β mRNA isoforms and protein in neuroblastoma. Apoptosis. 1996; 1:63.
19. Kuznetsov AV, Margreiter R. Heterogeneity of mitochondria and mitochondrial function within cells as another level of mitochondrial complexity. Int J Mol Sci. 2009; 10(4):1911–29. https://doi.org/10.3390/ijms10041911 PMID: 19468346
20. Jeon JH, Kim DK, Shin Y, Kim HY, Song B, Lee EY et al. Migration and invasion of drug-resistant lung adenocarcinoma cells are dependent on mitochondrial activity. Exp Mol Med. 2016; 48(12):e277. https://doi.org/10.1038/emm.2016.129 PMID: 27932791
21. Hughes MA, Harper N, Butterworth M, Cain K, Cohen GM, MacFarlane M. Reconstitution of the death-inducing signaling complex reveals a substrate switch that determines CD95-mediated death or survival. Mol Cell. 2009; 35(3):265–279. https://doi.org/10.1016/j.molcel.2009.06.012 PMID: 19683492
22. Wieder T, Essmann F, Prokop A, Schmelz K, Schulze-Osthoff K, Beyaert R, et al. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood. 2001; 97(5):1378–1387. PMID: 11222383
23. Ferreira KS, Kreutz C, Macnelly S, Neubert K, Haber A, Bogyo M, et al. Caspase-3 feeds back on caspase-8, Bid and XIAP in type I Fas signaling in primary mouse hepatocytes. Apoptosis. 2012; 17(5):503–515. https://doi.org/10.1007/s10495-011-0691-0 PMID: 22246639
24. Twiddy D, Cain K. Caspase-9 cleavage, do you need it? Biochem J. 2007; 405(1):e1–2. https://doi.org/10.1042/BJ20070617 PMID: 17555401
25. Hu Q, Wu D, Chen W, Yan Z, Yan C, He T et al. Proc Natl Acad Sci USA. 2014; 111(46):16254–61. https://doi.org/10.1073/pnas.1418000111 PMID: 25313070
26. Özören N, El-Deiry WS. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia. 2002; 4(6):551–557. https://doi.org/10.1088/sj/ne.7900270 PMID: 12407450
27. Samraj AK, Keil E, Ueffing N, Schulze-Osthoff K, Schmitz I. Loss of caspase-9 provides genetic evidence for the type I/II concept of CD95-mediated apoptosis. J Biol Chem. 2006; 281(40):29652–29659. https://doi.org/10.1074/jbc.M603487200 PMID: 16895904
28. Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 2002; 16(1):33–45. https://doi.org/10.1101/gad.949602 PMID: 11782443
29. Shawgo ME, Shelton SN, Robertson JD. Caspase-9 activation by the apoptosis is not required for Fas-mediated apoptosis in type II Jurkat cells. J Biol Chem. 2009; 284(48):33447–33455. https://doi.org/10.1074/jbc.M109.032359 PMID: 19758996
30. Jost PJ, Grabow S, Gray D, McKenzie MD, Nachbur U, Huang DC, et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature. 2008; 460(7258):1035–1039. https://doi.org/10.1038/nature08229 PMID: 19626005
31. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000; 102(1):33–42. PMID: 10929711
32. Fulda S. Smac mimetics as IAP antagonists. Semin Cell Dev Biol. 2015; 39:132–8. https://doi.org/10.1016/j.semcdb.2014.12.005 PMID: 25500219
33. Suzuki Y, Nakabayashi Y, Takahashi R. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci USA. 2001; 98(15):8662–8667. https://doi.org/10.1073/pnas.161506698 PMID: 11447297

34. Asthenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999; 104(2):155–162. https://doi.org/10.1172/JCI6926 PMID: 10411544

35. Lawrence D, Shahrokz Z, Marsters S, Achilles K, Shih D, Mounho B, et al. Differential hepatocytes toxicity of recombinant Apo2L/TRAIL versions. Nat Med. 2001; 7(4):383–385. https://doi.org/10.1038/86997 PMID: 11283636

36. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, et al. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med. 1993; 329(10):690–694. https://doi.org/10.1056/NEJM199309023291003 PMID: 8393963

37. Apolinario RM, van der Valk P, de Jong JS, Deville W, van Ark-Otte J, Dingemans AM, et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol. 1997; 15(6):2456–2466. https://doi.org/10.1200/JCO.1997.15.6.2456 PMID: 9196162

38. Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C et al. High expression of BCL-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677–81. https://doi.org/10.1038/nature03579 PMID: 15902208

39. Huang JQ, Liang HL, Jin TE, Xie Z. Altered expression profile of apoptosis-related molecules correlated with clinicopathological factors in non-small-cell lung cancer. Int J Clin Exp Pathol. 2015; 8(9):11278–86. PMID: 26647102

40. Abou El Hassan MA, Mastenbroek DC, Gerritsen WR, Giaccone G, Kruyt FA. Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenosine-mediated expression of full-length TRAIL. Br J Cancer. 2004; 91(1):171–177. https://doi.org/10.1038/sj.bjc.6601910 PMID: 15173960

41. Deeks ED. Venetoclax: First Global Approval. Drugs. 2016; 76(9):979–87. https://doi.org/10.1007/s40265-016-0596-x PMID: 27260335

42. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ; Belli BA et al. An inhibitor of Bcl-2 family proteins induces proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-ligand sensitive and insensitive cell lines. Cancer Res. 2000; 60(16):4525–4530. https://doi.org/10.1158/0008-5472.CAN-00-0559 PMID: 10911322

43. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ; Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677–81. https://doi.org/10.1038/nature03579 PMID: 15902208

44. Skommer J, Das SC, Nair A, Brittain T, Raychaudhuri S. Nonlinear regulation of commitment to apoptosis by simultaneous inhibition of Bcl-2 and XIAP in leukemia and lymphoma cells. Apoptosis. 2011; 16(6):619–26. https://doi.org/10.1007/s10495-011-0593-1 PMID: 21442307

45. Sun XM, Bratton SB, Butterworth M, MacFarlane M, Cohen GM. Bcl-2 and Bcl-xL inhibit CD95-mediated apoptosis by preventing mitochondrial release of Smac/DIABLO and subsequent inactivation of X-linked inhibitor-of-apoptosis protein. J Biol Chem. 2002; 277(13):11345–51. https://doi.org/10.1074/jbc.M109893200 PMID: 11805195

46. Würtzle ML, Laussmann MA, Rehm M. The central role of initiator caspase-9 in apoptosis signal transduction and the regulation of its activation and activity on the apoptosome. Exp Cell Res. 2012; 318(11):1213–1220. https://doi.org/10.1016/j.yexcr.2012.02.013 PMID: 22406265

47. Brentnall M, Rodrigue-Menocal L, De Guevara RL, Cepero E, Boise LH. Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. Exp Cell Res. 2013; 214(6):619–26. https://doi.org/10.1007/s10495-011-0593-1 PMID: 21442307

48. Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J, et al. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature. 2001; 410(6824):112–116. https://doi.org/10.1038/35065125 PMID: 11242052

49. Okada H, Suh WK, Jin J, Woo M, Du C, Elia A, et al. Generation and Characterization of Smac/DIA BLO-Deficient Mice. Mol Cell Biol. 2002; 22(10):3509–3517. https://doi.org/10.1128/MCB.22.10.3509-3517.2002 PMID: 11971981

50. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M et al. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro.
and in vivo. Cancer Res. 2008; 68(19):7956–65. https://doi.org/10.1158/0008-5472.CAN-08-1296 PMID: 18829553

52. Fakler M, Loeder S, Vogler M, Schneider K, Jeremias I, Debatin KM, et al. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood. 2009; 113(8): 1710–1722. https://doi.org/10.1182/blood-2007-09-114314 PMID: 19036706

53. Lovric MM, Hawkins CJ. TRAIL treatment provokes mutations in surviving cells. Oncogene. 2010; 29 (36): 5048–5060. https://doi.org/10.1038/onc.2010.242 PMID: 20639907

54. Ichim G, Lopez J, Ahmed SU, Muthalagu N, Giampazolias E, Delgado ME, et al. Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Mol Cell. 2015; 57(5):860–872. https://doi.org/10.1016/j.molcel.2015.01.018 PMID: 25702873

55. Möller Y, Siegemund M, Beyes S, Herr R, Lecis D, Delia D, et al. EGFR-Targeted TRAIL and a Smac Mimetic Synergize to Overcome Apoptosis Resistance in KRAS Mutant Colorectal Cancer Cells. PLoS One. 2014; 9(9): e107. https://doi.org/10.1371/journal.pone.0107165 PMID: 25198428

56. Rehm M, Huber HJ, Dussmann H, Prehn JH. Systems analysis of effector caspase activation and its control by X-linked inhibitor of apoptosis protein. EMBO J. 2006; 25(18):4338–49. https://doi.org/10.1038/sj.emboj.7601295 PMID: 16932741

57. Schmid J, Dussmann H, Boukes GJ, Flanagan L, Lindner AU, O’Connor CL et al. Systems analysis of cancer cell heterogeneity in caspase-dependent apoptosis subsequent to mitochondrial outer membrane permeabilization. J Biol Chem. 2012; 287(49):41546–59. https://doi.org/10.1074/jbc.M112.411827 PMID: 23038270